Assignment
In patients with cystinosis, crystals accumulate in the eyes, causing vision problems such as light sensitivity, corneal damage and blurred vision. Treatment consists of eye drops taken every waking hour, previously available only through a free clinical trial that spanned two decades. With the launch of Sigma-Tau’s new product, patients with this rare disease finally gained access to an approved treatment. SmithSolve was tasked with easing the transition for patients to commercial therapy and encouraging them to comply with the dosing schedule